
Dec 16 (Reuters) - Immunitybio Inc IBRX.O:
ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-ONLY NON-MUSCLE INVASIVE BLADDER CANCER
IMMUNITYBIO INC - ANKTIVA PLUS BCG SHOWS TOLERABLE SAFETY PROFILE